Pitkänen Asla, Lukasiuk Katarzyna, Dudek F Edward, Staley Kevin J
Department of Neurobiology, A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, FI-70211 Kuopio, Finland Department of Neurology, Kuopio University Hospital, FI-70211 Kuopio, Finland.
The Nencki Institute of Experimental Biology, Polish Academy of Sciences, 02-093 Warsaw, Poland.
Cold Spring Harb Perspect Med. 2015 Sep 18;5(10):a022822. doi: 10.1101/cshperspect.a022822.
Epileptogenesis is a chronic process that can be triggered by genetic or acquired factors, and that can continue long after epilepsy diagnosis. In 2015, epileptogenesis is not a treatment indication, and there are no therapies available in clinic to treat individuals at risk of epileptogenesis. However, thanks to active research, a large number of animal models have become available for search of molecular mechanisms of epileptogenesis. The first glimpses of treatment targets and biomarkers that could be developed to become useful in clinic are in sight. However, the heterogeneity of the epilepsy condition, and the dynamics of molecular changes over the course of epileptogenesis remain as challenges to overcome.
癫痫发生是一个慢性过程,可由遗传或后天因素引发,且在癫痫诊断后仍会持续很长时间。2015年时,癫痫发生并非一种治疗指征,临床上也没有疗法可用于治疗有癫痫发生风险的个体。然而,由于积极的研究,现已获得大量动物模型用于探寻癫痫发生的分子机制。有望开发出可应用于临床的治疗靶点和生物标志物的初步迹象已经显现。然而,癫痫病症的异质性以及癫痫发生过程中分子变化的动态性仍是有待克服的挑战。